GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Short-Term Debt

ME Therapeutics Holding (XCNQ:METX) Short-Term Debt : C$0.00 Mil (As of Feb. 2025)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Short-Term Debt?

ME Therapeutics Holding's Short-Term Debt for the quarter that ended in Feb. 2025 was C$0.00 Mil.

ME Therapeutics Holding's annual Short-Term Debt declined from Aug. 2022 (C$0.13 Mil) to Aug. 2023 (C$0.04 Mil) and declined from Aug. 2023 (C$0.04 Mil) to Aug. 2024 (C$0.00 Mil).


ME Therapeutics Holding Short-Term Debt Historical Data

The historical data trend for ME Therapeutics Holding's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Short-Term Debt Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24
Short-Term Debt
0.13 0.04 -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ME Therapeutics Holding Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


ME Therapeutics Holding Short-Term Debt Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding Business Description

Traded in Other Exchanges
Address
177 Robson St., Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding Headlines

No Headlines